ADD/ADHD News

Recent findings indicated treatment with methylphenidate for attention-deficit/hyperactivity disorder significantly affected the dopaminergic system in children but not adults.

Tris Pharma Inc. recently announced the launch of a new website for health care professionals prescribing Dyanavel XR, extended-release oral suspension, CII, an extended-release liquid amphetamine, for attention-deficit/hyperactivity disorder in children aged 6 years and older.

Children with atopic diseases such as asthma, allergic rhinitis, or eczema, and those whose parents who were exposed to attention-deficit/hyperactivity disorder and atopic disease medications, were more susceptible to developing ADHD, according to study results.

From 2010 to 2014, prescribed stimulant use significantly increased among adults, while youth experienced a moderate increase.

SHP465-306, a triple-bead mixed amphetamine salts capsule from Shire, was effective and safe for attention-deficit/hyperactivity disorder, according to recent findings.

Recent findings showed a significant proportion of individuals with late-onset attention-deficit/hyperactivity disorder did not meet criteria in childhood, suggesting that a lack of a childhood diagnosis should not preclude late-onset diagnosis in adulthood.

The FDA recently accepted an investigational new drug submitted by NLS Pharma for mazindol, a norepinephrine and dopamine reuptake inhibitor, to treat attention-deficit/hyperactivity disorder in adults.

Symptoms of psychiatric disorders were more common among individuals who met criteria for workaholism than those who did not, according to recent findings.

Recent findings indicated distinct developmental trajectories between childhood and adulthood attention-deficit/hyperactivity disorder, suggesting that the theory that adulthood attention-deficit/hyperactivity disorder is a continuation of childhood attention-deficit/hyperactivity disorder is incorrect.

Use of methylphenidate among children and adolescents for treatment of attention-deficit/hyperactivity disorder slightly increased the RR for cardiovascular events, such as myocardial infarction and arrhythmias, according to recent research in BMJ.